Lymphopenia is not associated with efficacy and risk of adverse events in a real-life MS population treated with fingo-limod and dimethyl fumarate

MLA

Bruschi, N., et al. Lymphopenia Is Not Associated with Efficacy and Risk of Adverse Events in a Real-Life MS Population Treated with Fingo-Limod and Dimethyl Fumarate. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4b6759d350c017b40ec3ec87cf7b9100&authtype=sso&custid=ns315887. Accessed 18 Nov. 2024.

APA

Bruschi, N., Boffa, G., Cellerino, M., Sbragia, E., Novi, G., Lapucci, C., Carpaneto, S., Laroni, A., Capello, E., Antonio UCCELLI, & Inglese, M. (n.d.). Lymphopenia is not associated with efficacy and risk of adverse events in a real-life MS population treated with fingo-limod and dimethyl fumarate.

Chicago

Bruschi, N., G. Boffa, M. Cellerino, E. Sbragia, G. Novi, C. Lapucci, S. Carpaneto, et al. 2024. “Lymphopenia Is Not Associated with Efficacy and Risk of Adverse Events in a Real-Life MS Population Treated with Fingo-Limod and Dimethyl Fumarate.” Accessed November 18. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.dedup.wf.001..4b6759d350c017b40ec3ec87cf7b9100&authtype=sso&custid=ns315887.